These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 34716207)
1. Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma. Evers M; Stip M; Keller K; Willemen H; Nederend M; Jansen M; Chan C; Budding K; Nierkens S; Valerius T; Meyer-Wentrup F; Eijkelkamp N; Leusen J J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34716207 [TBL] [Abstract][Full Text] [Related]
2. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models. Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484 [TBL] [Abstract][Full Text] [Related]
3. Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockade. Chan C; Stip M; Nederend M; Jansen M; Passchier E; van den Ham F; Wienke J; van Tetering G; Leusen J J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782540 [TBL] [Abstract][Full Text] [Related]
4. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106 [TBL] [Abstract][Full Text] [Related]
5. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328 [TBL] [Abstract][Full Text] [Related]
6. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma. Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742 [TBL] [Abstract][Full Text] [Related]
7. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy. Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879 [TBL] [Abstract][Full Text] [Related]
8. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646 [TBL] [Abstract][Full Text] [Related]
9. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment. Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929 [TBL] [Abstract][Full Text] [Related]
10. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies. Parsons K; Bernhardt B; Strickland B Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066 [TBL] [Abstract][Full Text] [Related]
11. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727 [TBL] [Abstract][Full Text] [Related]
12. Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3). Arendt AM; Heubach F; Maier CP; Giardino S; Jung G; Kowalewski E; Rabsteyn A; Amorelli G; Seitz C; Schlegel P; Handgretinger R; Lang P Cancer Immunol Immunother; 2023 Nov; 72(11):3813-3824. PubMed ID: 37742286 [TBL] [Abstract][Full Text] [Related]
13. Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG. Brandsma AM; Bondza S; Evers M; Koutstaal R; Nederend M; Jansen JHM; Rösner T; Valerius T; Leusen JHW; Ten Broeke T Front Immunol; 2019; 10():704. PubMed ID: 31031746 [TBL] [Abstract][Full Text] [Related]
15. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. Voeller J; Sondel PM J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608 [TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin? Uttenreuther-Fischer MM; Krüger JA; Fischer P J Immunol; 2006 Jun; 176(12):7775-86. PubMed ID: 16751426 [TBL] [Abstract][Full Text] [Related]
17. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy. Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879 [TBL] [Abstract][Full Text] [Related]
20. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]